Endoscopy Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Gastroenterol Res Pract. 2012;2012:728454. doi: 10.1155/2012/728454. Epub 2012 Jan 12.
Introduction. In Japan, the cost-effectiveness of total colonoscopy (TCS) for primary screening of colorectal cancer (CRC) is unclear. We compared the cost of identifying a patient with CRC using two primary screening strategies: TCS (strategy 1) and the immunochemical fecal test (FIT) (strategy 2). Materials and Methods. We retrospectively analyzed the TCS screening database at our institution from February 2004 to August 2010 (strategy 1, n = 15,348) and the Japanese nationwide survey of CRC screening in 2008 (strategy 2, n = 5,267,443). Results. 112 and 6,838 CRC cases were detected in strategies 1 and 2, costing 2,124,000 JPY and 1,629,000 JPY, respectively. The rate of earlier-stage CRC was higher in strategy 1. Conclusions. The cost was higher using TCS as a primary screening procedure. However, the difference was not excessive, and considering the increased rate of detecting earlier CRC, the use of TCS as a primary screening tool may be cost-effective.
简介。在日本,全结肠镜检查(TCS)用于结直肠癌(CRC)初级筛查的成本效益尚不清楚。我们比较了两种初级筛查策略(TCS 策略 1 和免疫化学粪便检测(FIT)策略 2)用于发现 CRC 患者的成本。
材料与方法。我们回顾性分析了 2004 年 2 月至 2010 年 8 月在我院的 TCS 筛查数据库(策略 1,n=15348)和 2008 年日本全国 CRC 筛查调查(策略 2,n=5267443)。
结果。在策略 1 和 2 中分别发现了 112 例和 6838 例 CRC 病例,成本分别为 2124000 日元和 1629000 日元。策略 1 中早期 CRC 的检出率更高。
结论。作为初级筛查程序,使用 TCS 的成本更高。然而,差异并不太大,并且考虑到更早发现 CRC 的比例增加,使用 TCS 作为初级筛查工具可能具有成本效益。